Photo - Remedium Bio
53023

Remedium Bio

We believe that any disease can be cured.

USA, Massachusetts
Market: Medicine, Pharmacology
Stage of the project: Prototype or product is ready

Date of last change: 07.07.2021
Show contacts
1
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

Our lead candidate is a first-in-class, single injection treatment, based on a clinically proven mechanism capable of regenerating cartilage in Osteoarthritis ($38B global market, 9% CAGR).

Current Status

Remedium has secured Seed financing of $1.2M, filed IP, onboarded KOLs, built the prototypes, and initiated in vitro efficacy studies. The company is currently in the process of finalizing a pivotal academic collaboration that will enable the completion of in vitro, ex vivo, and in vivo efficacy studies. The expanded seed of additional $2.3M will enable a transformational Series A raise in early 2022.

Market

All moderate to severe osteoarthritis patients, excluding bone-on-bone cases can potentially benefit from this technology. Of the $38B Total Addressable Market (TAM) (globally), we believe that $20B is available as the Serviceable Attainable Market (SAM).

Problem or Opportunity

Osteoarthritis (OA) is a debilitating progressive disease affecting 33 million Americans, or 1 in 7 US adults. All currently approved treatments are palliative and many patients end up progressing to joint replacement surgery. OA is a significant burden on patients and society accounting for over $16.5 billion in health care costs and 4.3% of the combined costs for all hospitalizations according to the CDC.

Solution (product or service)

Remedium has patented and built prototypes of an FGF-18 gene therapy, using the clinically proven mechanism of action of FGF-18 and an approved delivery vector. The FGF-18 gene therapy is the only treatment potentially capable of regenerating cartilage in Osteoarthritis after a single injection.

Competitors

All currently approved treatments are strictly palliative, offering no ability to regenerate cartilage in Osteoarthritis. Furthermore, the effect of most treatments is very minimal, oftentimes showing little improvement over a placebo injection. Only FGF-18 protein injections have been demonstrated to increase cartilage thickness in controlled, randomized clinical trials. However, they require a regimen of 3x-weekly injections every 6 months (indefinitely) to sustain effect. Remedium is developing the only patented gene therapy treatment based on this clinically proven mechanism, creating the potential to regenerate cartilage with a single injection.

Advantages or differentiators

Remedium has the only, single-injection gene therapy based on the clinically proven mechanism of FGF-18. The treatment could potentially enable multi-year (5+) sustained efficacy after a single injection of the therapeutic.

Money will be spent on

Completing in vitro, ex vivo, and in vivo efficacy studies enabling a transformational Series A raise for the company.

Team or Management

Won the competition and other awards

Selected as the Finalist at the Octane OC investment competition in 2020.

Invention/Patent

Several provisional applications have been filed, one PCT application has been filed and published.
4,00
1
2
3
4
5
3 voices
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility94
star0
Add to favorites
Delete from favorites
share
close
thumb_up1
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video